Representative(s):

Stacy Voight
stacyl@gene.com
920-420-0422

Sara Volz
volz.sara@gene.com
715-499-2397

Joyce Girard
joyceg@gene.com
414-881-8901

We will be available to you before, during and after presentation.

Genentech is advocating for solutions and policies that help to advance scientific innovation and ensure patients have access to the medicines they need.

Visit our website to learn more:  www.gene.com

 

Tecentriq- As a single agent, is indicated as adjuvant treatment following resection & platinum based chemo for adults with stage 2-3a NSCLC who tumors have >1% PD-L1 of tumor cells as determined by FDA approved test.

PDF icon GNE Lung Cancer Portfolio Interactive PDF

PDF icon A Treatment Option for mHCC Clinical Brochure.pdf

Phesgo-Fixed dose, subcutaneous formulation of Perjeta & Trastuzumab for Her 2+ early and metastatic breast cancer patients that is administered in approximately 5 mins.

PDF icon PHESGO HCP Clinical Brochure